These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 4456821)
1. Current concepts in the management of Parkinson's disease. Chapman WG West Indian Med J; 1974 Mar; 23(1):61-4. PubMed ID: 4456821 [No Abstract] [Full Text] [Related]
2. [Medical treatment of Parkinson's disease]. Castaigne P; Rondot P; Ribadeau-Dumas JL Ann Med Interne (Paris); 1972 Apr; 123(4):357-64. PubMed ID: 5077040 [No Abstract] [Full Text] [Related]
3. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease. Andrews CJ; Somerville B Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384 [No Abstract] [Full Text] [Related]
4. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients]. Ferel D Schweiz Med Wochenschr; 1972 Jan; 102(3):88-94. PubMed ID: 4551909 [No Abstract] [Full Text] [Related]
5. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor]. Görlich J; Markus E Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316 [No Abstract] [Full Text] [Related]
6. [Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)]. Schneider E; Fischer PA; Jacobi P Med Klin; 1974 Mar; 69(13):541-5. PubMed ID: 4831456 [No Abstract] [Full Text] [Related]
7. [Dopa and decarboxylase inhibitors in Parkinson's disease]. Pakkenberg H Ugeskr Laeger; 1974 Feb; 136(7):377. PubMed ID: 4821980 [No Abstract] [Full Text] [Related]
8. [Cardiovascular effects of L-dopa and decarboxylase inhibitor on patients with Parkinson's disease]. Desjacques P; Moret P; Gauthier G Schweiz Med Wochenschr; 1973 Dec; 103(50):1783-5. PubMed ID: 4129257 [No Abstract] [Full Text] [Related]
9. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study]. Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149 [No Abstract] [Full Text] [Related]
10. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor]. Stammler A; Vielhaber K Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521 [No Abstract] [Full Text] [Related]
11. [Dopa metabolism in relation to the therapy of Parkinson's syndrome]. Pletscher A; Bartholini G Actual Pharmacol (Paris); 1971; 24():27-49. PubMed ID: 5150621 [No Abstract] [Full Text] [Related]
12. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)]. Steinhäusl H Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743 [No Abstract] [Full Text] [Related]
13. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study]. Tissot R; de Ajuriaguerra J Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226 [No Abstract] [Full Text] [Related]
14. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa. Fermaglich J Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167 [No Abstract] [Full Text] [Related]
15. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor]. Guillard A Brux Med; 1972 Oct; 52(10):673-80. PubMed ID: 4656191 [No Abstract] [Full Text] [Related]
16. [Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor]. Fischer PA; Schneider E; Jacobi P; Maxion H Med Welt; 1973 Nov; 24(45):1742-6. PubMed ID: 4768206 [No Abstract] [Full Text] [Related]
17. L-dopa in Parkinson's disease. A report on 95 cases and review of the literature. Lewis I J Med Assoc State Ala; 1971 May; 40(11):709-18. PubMed ID: 5573008 [No Abstract] [Full Text] [Related]
18. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?]. Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694 [No Abstract] [Full Text] [Related]
19. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)]. Gehlen W; Eisenlohr JJ Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993 [No Abstract] [Full Text] [Related]
20. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)]. Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970 [No Abstract] [Full Text] [Related] [Next] [New Search]